VTE
NICE recommends Daiichi’s Lixiana for blood clots
July 13, 2015Sales and Marketing DVT, Daiichi, Daiichi Sankyo, Lixiana, NICE, NOACs, VTE, anticoagulant, blood clots, edoxaban, novel anticoagulant. PE
Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug …
Daiichi Sankyo launches clotting drug Lixiana in UK
July 10, 2015Medical Communications, Sales and Marketing Daiichi Sankyo, Lixiana, NOAC, VTE, anticoagulant, atrial fibrillation, blood clots, edoxaban, novel anticoagulant, strokes, warfarin
Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.Lixiana (edoxaban) …
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
Edoxaban ‘as effective as warfarin’
September 2, 2013Sales and Marketing DVT, Daiichi Sankyo, VTE, warfarin
Daiichi Sankyo is celebrating after its once-a-day blood thinner edoxaban proved as effective as warfarin in a late-stage trial, although …
EMA starts contraceptive safety review
January 30, 2013Manufacturing and Production, Sales and Marketing EMA, PRAC, VTE, contraception
Europe’s health regulator is to examine the safety of newer forms of contraceptive pills following concerns over potential health risks …
NICE yes for Xarelto to treat blood clots
July 25, 2012Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto
NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …
Eliquis launched in the UK
September 19, 2011Sales and Marketing Eliquis, Pradaxa, VTE, Xarelto
Eliquis, the latest entrant to the competitive oral anticoagulant market, has been launched in the UK.Co-developed and co-marketed by Pfizer …
Digital Pharma: online campaign directory updated
March 4, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra
The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …
Digital Pharma: NHS thrombosis e-learning
January 14, 2011Medical Communications Bayer, Boehringer Ingelheim, Digital Pharma blog, NHS training, Pfizer, Sanofi-Aventis, VTE, e-learning, venous thromboembolism
The NHS has launched a best-practice website to help educate healthcare professionals about one of the most common causes of …
VTE trial boost for Pfizer and BMS’ apixaban
December 31, 2010Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism
Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …
New anti-clotting drugs: stopping the silent killers
June 28, 2010Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis
Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …
Encouraging data for ThromboGenics and BioInvent product
May 7, 2010BioInvent, Lovenox, ThromboGenics, VTE
An antibody-based drug to prevent blood clots after orthopaedic surgery has shown promising results in phase II. TB-402 is a …
Patients ignorant of blood clot risks
April 14, 2010Sales and Marketing Pradaxa, VTE, thrombosis
Many patients are not aware that they are at risk from blood clots when staying in hospital, according to new …
Study boost for atrial fibrillation drugs
March 17, 2010Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban
Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …
Phase III success for apixaban
March 5, 2010Research and Development BMS, Pfizer, VTE, apixaban
Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …
